GRA new study published in the 'Annals of Internal Medicine' suggests that the shingles vaccine (RZV) may reduce the risk of developing dementia in individuals aged 66 and older. The research analyzed data from over half a million people in nursing homes in the United States between January 2017 and December 2022. It found that those who received at least one dose of the RZV within a year of entering or leaving a nursing home had a significantly lower risk of being diagnosed with dementia over the next four years compared to those who did not receive the vaccine. The study used a method called 'target trial emulation,' which mimics randomized clinical trials using real-world data. Researchers noted that while vaccinated individuals were slightly younger and healthier overall, they still observed a 24% reduction in dementia risk among those who received the vaccine. This finding supports earlier observational studies linking the shingles vaccine to reduced dementia risk.
Bias read (Center): The article presents findings from a medical study without overtly favoring any political perspective. It focuses on health outcomes related to vaccination and does not involve political figures, policies, or ideological debates.
